Unknown

Dataset Information

0

Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.


ABSTRACT: Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in the serum. It is incurable with current therapy, and the decision to treat patients as well as the choice of treatment can be complex. Using a risk-adapted approach, we provide recommendations on timing and choice of therapy. Patients with smoldering or asymptomatic Waldenström macroglobulinemia and preserved hematologic function should be observed without therapy. Symptomatic patients with modest hematologic compromise, IgM-related neuropathy that requires therapy, or hemolytic anemia unresponsive to corticosteroids should receive standard doses of rituximab alone without maintenance therapy. Patients who have severe constitutional symptoms, profound hematologic compromise, symptomatic bulky disease, or hyperviscosity should be treated with the DRC (dexamethasone, rituximab, cyclophosphamide) regimen. Any patient with symptoms of hyperviscosity should first be treated with plasmapheresis. For patients who experience relapse after a response to initial therapy of more than 2 years' duration, the original therapy should be repeated. For patients who had an inadequate response to initial therapy or a response of less than 2 years' duration, an alternative agent or combination should be used. Autologous stem cell transplant should be considered in all eligible patients with relapsed disease.

SUBMITTER: Ansell SM 

PROVIDER: S-EPMC2931618 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Ansell Stephen M SM   Kyle Robert A RA   Reeder Craig B CB   Fonseca Rafael R   Mikhael Joseph R JR   Morice William G WG   Bergsagel P Leif PL   Buadi Francis K FK   Colgan Joseph P JP   Dingli David D   Dispenzieri Angela A   Greipp Philip R PR   Habermann Thomas M TM   Hayman Suzanne R SR   Inwards David J DJ   Johnston Patrick B PB   Kumar Shaji K SK   Lacy Martha Q MQ   Lust John A JA   Markovic Svetomir N SN   Micallef Ivana N M IN   Nowakowski Grzegorz S GS   Porrata Luis F LF   Roy Vivek V   Russell Stephen J SJ   Short Kristen E Detweiler KE   Stewart A Keith AK   Thompson Carrie A CA   Witzig Thomas E TE   Zeldenrust Steven R SR   Dalton Robert J RJ   Rajkumar S Vincent SV   Gertz Morie A MA  

Mayo Clinic proceedings 20100811 9


Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in the serum. It is incurable with current therapy, and the decision to treat patients as well as the choice of treatment can be complex. Using a risk-adapted approach, we provide recommendations on timing and choice of therapy. Patients with smoldering or asymptomatic Waldenström macroglobulinemia and preserved hematologi  ...[more]

Similar Datasets

| S-EPMC5556979 | biostudies-literature
| S-EPMC5554888 | biostudies-other
| S-EPMC2787395 | biostudies-literature
| S-EPMC7727571 | biostudies-literature
| S-EPMC9362871 | biostudies-literature
| S-EPMC5354523 | biostudies-literature
| S-EPMC10107762 | biostudies-literature
| S-EPMC5928091 | biostudies-literature
| S-EPMC5189618 | biostudies-literature
| S-EPMC2943754 | biostudies-literature